(Q40885155)

24 September 2017

title

Effect of protease inhibitors on HIV-1 maturation and infectivity (English)

1 reference

24 September 2017

1 reference

Jardine DK

1

1 reference

24 September 2017

Tyssen DP

series ordinal

2

1 reference

24 September 2017

Birch CJ

series ordinal

3

1 reference

24 September 2017

publication date

1 January 2000

1 reference

24 September 2017

1 reference

24 September 2017

volume

45

1 reference

24 September 2017

issue

1

1 reference

24 September 2017

page(s)

59-68

1 reference

Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900074-1

7 January 2021

A C2 symmetry-based HIV protease inhibitor, A77003, irreversibly inhibits infectivity of HIV-1 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900074-1

7 January 2021

Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900074-1

7 January 2021

Active human immunodeficiency virus protease is required for viral infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900074-1

7 January 2021

Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900074-1

7 January 2021

Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900074-1

7 January 2021

A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900074-1

7 January 2021

Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900074-1

7 January 2021

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900074-1

7 January 2021

Rational design of peptide-based HIV proteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900074-1

7 January 2021

Analysis of non-infectious HIV particles produced in presence of HIV proteinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900074-1

7 January 2021

Investigation of Topoisomerase Inhibitors for Activity against Human Immunodeficiency Virus: Inhibition by Coumermycin A1

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900074-1

7 January 2021

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2899%2900074-1

7 January 2021

10.1016/S0166-3542(99)00074-1

Identifiers

DOI

1 reference

24 September 2017

1 reference